• Home
  • CPD Activities
  • Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents

Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents

NameWorld Continuing Education Alliance
Activity TitleStatin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents
DetailsStatin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents
CompetenceGeneral Medicine
Start Date<span class="not-set">(not set)</span>
End Date<span class="not-set">(not set)</span>
Event Time10:30 AM
LocationWorld Continuing Education Alliance eLearning System
Cost (UGX)0
CPD Points1